New indications for exenatide therapy of type 2 diabetes mellitus

Obesity associated with the enhanced risk of cardiovascular disorders plays a key role in the evolvement and progression of type 2 diabetes mellitus(DM2). Incretin mimetics are the sole class of hypoglycemic agents that not only effectively correct hyperglycemia but also reduce body weight. Exenatid...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Olga Konstantinovna Vikulova, Marina Vladimirovna Shestakova
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2010
Materias:	type 2 diabetes mellitus obesity incretin mimetics exenatide byetta Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/966c47654fdf45d8a1986ff7d62d681c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:966c47654fdf45d8a1986ff7d62d681c
record_format	dspace
spelling	oai:doaj.org-article:966c47654fdf45d8a1986ff7d62d681c2021-11-14T09:00:15ZNew indications for exenatide therapy of type 2 diabetes mellitus2072-03512072-037810.14341/2072-0351-5496https://doaj.org/article/966c47654fdf45d8a1986ff7d62d681c2010-09-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/5496https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Obesity associated with the enhanced risk of cardiovascular disorders plays a key role in the evolvement and progression of type 2 diabetes mellitus(DM2). Incretin mimetics are the sole class of hypoglycemic agents that not only effectively correct hyperglycemia but also reduce body weight. Exenatide(Byetta) is the first drug of this class approved for the use as monotherapy. This paper presents a detailed review of the available data on thescope of exenatide effects and the results of its clinical studies that confirm high efficiency of Byetta used for both monotherapy and combined therapyof DM2.Olga Konstantinovna VikulovaMarina Vladimirovna ShestakovaEndocrinology Research Centrearticletype 2 diabetes mellitusobesityincretin mimeticsexenatidebyettaNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 13, Iss 3, Pp 98-104 (2010)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	type 2 diabetes mellitus obesity incretin mimetics exenatide byetta Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	type 2 diabetes mellitus obesity incretin mimetics exenatide byetta Nutritional diseases. Deficiency diseases RC620-627 Olga Konstantinovna Vikulova Marina Vladimirovna Shestakova New indications for exenatide therapy of type 2 diabetes mellitus
description	Obesity associated with the enhanced risk of cardiovascular disorders plays a key role in the evolvement and progression of type 2 diabetes mellitus(DM2). Incretin mimetics are the sole class of hypoglycemic agents that not only effectively correct hyperglycemia but also reduce body weight. Exenatide(Byetta) is the first drug of this class approved for the use as monotherapy. This paper presents a detailed review of the available data on thescope of exenatide effects and the results of its clinical studies that confirm high efficiency of Byetta used for both monotherapy and combined therapyof DM2.
format	article
author	Olga Konstantinovna Vikulova Marina Vladimirovna Shestakova
author_facet	Olga Konstantinovna Vikulova Marina Vladimirovna Shestakova
author_sort	Olga Konstantinovna Vikulova
title	New indications for exenatide therapy of type 2 diabetes mellitus
title_short	New indications for exenatide therapy of type 2 diabetes mellitus
title_full	New indications for exenatide therapy of type 2 diabetes mellitus
title_fullStr	New indications for exenatide therapy of type 2 diabetes mellitus
title_full_unstemmed	New indications for exenatide therapy of type 2 diabetes mellitus
title_sort	new indications for exenatide therapy of type 2 diabetes mellitus
publisher	Endocrinology Research Centre
publishDate	2010
url	https://doaj.org/article/966c47654fdf45d8a1986ff7d62d681c
work_keys_str_mv	AT olgakonstantinovnavikulova newindicationsforexenatidetherapyoftype2diabetesmellitus AT marinavladimirovnashestakova newindicationsforexenatidetherapyoftype2diabetesmellitus
_version_	1718429595956412416

New indications for exenatide therapy of type 2 diabetes mellitus

Ejemplares similares